Services on Demand
- Cited by SciELO
- Access statistics
- Similars in SciELO
Print version ISSN 1679-4508
Einstein (São Paulo) vol.10 no.2 São Paulo Apr./June 2012
Livia Almeida DutraI; Pedro Braga-NetoI; José Luiz PedrosoI; Orlando Graziani Povoas BarsottiniII
IDepartament of Neurology and Neurosurgery, Universidade Federal de São Paulo UNIFESP São Paulo (SP), Brazil
IIDepartament of Neurology and Neurosurgery, Universidade Federal de São Paulo UNIFESP, São Paulo (SP), Brazil; Instituto do Cérebro InCe Hospital Israelita Albert Einstein HIAE, São Paulo (SP), Brazil
The Sneddon's syndrome is a rare disorder characterized by the occurrence of cerebrovascular disease associated with livedo reticularis. The antiphospholipid syndrome is the most frequent type of acquired thrombophilia, defined by the occurrence of thrombosis or pregnancy morbidity in the presence of persistently positive antiphospholipid antibodies. Approximately 80% of Sneddon's syndrome patients have an antiphospholipid antibody marker. These antibodies may play a pathogenetic role in some cases of Sneddon's syndrome, and many authors consider these two syndromes as the same entity. Although clinical features of antiphospholipid syndrome and Sneddon's syndrome may overlap, there is a distinction between clinical and laboratory evidence suggesting that these two entities are different diseases. A recent finding of coagulopathies, including elevated levels of coagulation factor VII, decreased levels of protein S, and activated protein C in Sneddon's syndrome patients suggested a possible biological link between the vasculopathy and a primary coagulopathy. Moreover, the clinical course seems to be progressive in Sneddon's syndrome patients and includes increase of disability and cognitive deterioration, more arterial involvement, and the antiphospholipid syndrome shows a more benign course. Both syndromes share clinical and laboratory features, and whether Sneddon's syndrome represents a spectrum of antiphospholipid syndrome remains unclear. Sneddon's syndrome patients have a worse prognosis and may represent a subgroup of patients who demands more rigorous follow-up. It is important to recognize the Sneddon's syndrome, particularly because stroke episodes may be prevented through appropriate treatment.
Keywords: Sneddon syndrome/immunology; Antiphospholipid syndrome/ immunology; Antibodies, anticardiolipin; Antibodies, antiphospholipid; Livedo reticularis; Stroke; Case reports
Sneddon's syndrome (SS) is a rare disorder characterized by the occurrence of cerebrovascular disease like stroke or transitory ischemic attack associated with livedo reticularis(1). Patients may have positive antiphospholipids (aPLs) antibodies and other manifestations of primary antiphospholipid syndrome (APS). We report a case of SS, and discuss its relation with APS.
A 41-year-old woman was referred to neurologic evaluation due to recurrent episodes of paresthesia in upper limbs for the last 20 years, lengthening for 20 minutes each episode. Twenty months before she presented an abrupt dysarthria and right hemiparesis that did not recover. At that time she was admitted for investigation. The patient developed arterial obstruction on her left foot two years before, which made her fourth toe turns blue and numb. She smoked for twenty years, had two first-trimester miscarriages and was receiving enalapril 10mg per day for hypertension. The patient denied any episodes of thrombosis, photosensibility, arthralgias, malar rash or oral ulcers.
General examination showed livedo reticularis involving abdominal region and upper limbs (Figure 1) and normal pulmonary and cardiac auscultation. A cold blue fourth pododactile was evident. Neurological examination revealed mild proportionate right hemiparesis with hyperreflexia and preserved sensory functions. Brain magnetic resonance imaging disclosed multiple white-matter abnormalities at frontal cortico-subcortical region suggesting involvement of small-vessels (Figure 2). Spinal fluid analysis showed elevated protein (64mg/dL) and transthoracic echocardiography, mild left atrial enlargement, thickening of the mitral valve with discrete reflux. The anticardiolipin antibodies (aCL) and the lupic anticoagulant were negative.
The patient was diagnosed as SS, and after three months of follow-up showed elevated IgM aCL titers that remained positive for 6 months. She was treated with oral anticoagulation.
APS is the most frequent type of acquired thrombophilia, defined by the occurrence of thrombosis or pregnancy morbidity in the presence of persistently positive aPL antibodies(2,3). Three aPL antibodies may be found in APS: aCL (60 to 70%), lupus anticoagulant (20 to 30%) and beta2-glycoprotein (5 to 10%). The aPLs antibodies promote activation of endothelial cells, monocytes, and platelets; and overproduction of tissue factor and thromboxane A2. Complement activation might have a central pathogenetic role(2).
The estimated annual incidence of SS is four cases per million and its precise etiology is unknown(1). The cardinal manifestation of livedo reticularis results from thrombosis of subcutaneous arterioles and compensatory capillary dilation that causes blood to stagnate, which on the other hand causes mottled discoloration(3).Histopathological analysis revealed a non-inflammatory thrombotic vasculopathy of the small and medium arteries of skin and brain(1,4).
Approximately 41% of SS present aCL antibodies(4). When other aPL antibodies were evaluated, such as anti-protrombin, lupus anticoagulant and anti-phosphatidilethanolamine, almost 80% of SS patients had an aPL marker(1,5,6). However, in many cases no antibodies could be found(7). These antibodies may play a pathogenetic role in some cases of SS. In addition, some authors consider SS and APS as the same entity(3,4,6,8).
Besides autoimmunity markers, SS and APS share clinical manifestations such as headache, hypertension, vascular dementia, involvement of cardiac valves and kidneys. Recurrent miscarriages and thrombosis could also be found in SS without aPL antibodies(1,4,8). Other dermatological manifestations include acrocyanosis, Raynaud's phenomenon and, less frequently, circumscribed skin necrosis(8).
It is important to determine the occurrence of cardiac manifestations in APS and SS patients. Studies suggest that valvulopathy might be a source for emboli and a possible cause of ischemic stroke. Also, there is an association between valvular heart disease and several central nervous disease manifestations in aPL positive patients, not only regarding stroke and transient ischemic attack(3).
Although clinical features of APS and SS may overlap, there is distinctive clinical and laboratory evidence suggesting that these two entities are different diseases(5). Several associated coagulopathies, including elevated levels of coagulation factor VII, decreased levels of protein S, and activated protein C resistance have been observed, suggesting a possible biological link between the vasculopathy and a primary coagulopathy in SS(3,8). Moreover, the clinical course seems to be progressive in SS patients and includes increase of disability and cognitive deterioration, more arterial involvement. APS shows a more benign course(4). Despite abnormalities in thrombotic mechanisms have been described, they have not been confirmed in large series, and the presence of aPL remains the most reliable explanation for the thrombotic process, but it accounts only for a subset of SS patients(8).
Considering secondary thromboprophylaxis, the main treatment for APS patients is anticoagulation rather than immunosuppression(2,3). For SS patients with aPL antibodies warfarin is often used(1,5). On the other hand, one study demonstrated that SS patients without aPL benefit from antiplatelet therapy(9).
Our patient had livedo reticularis, pregnancy morbidity, cardiac valvular disorder and probably arterial thrombosis in inferior limbs, which are commonly associated to both disorders. In the light of information exposed, she was diagnosed as SS with positive aPL antibodies, therefore requiring anticoagulation.
In conclusion, the SS and the APS share clinical and laboratory features, and whether SS represents a spectrum of APS remains unclear. SS patients have a worse prognosis and may represent a subgroup of patients who demands more rigorous follow-up. It is important to recognize the SS, particularly because stroke episodes may be prevented through appropriate treatment.
1. Aladdin Y, Hamadeh M, Butcher K. The Sneddon syndrome. Arch Neurol. 2008;65(6):834-5. [ Links ]
2. Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA. Antiphospholipid syndrome. Lancet. 2010;376(9751):1498-509. [ Links ]
3. Sanna G, D'Cruz D, Cuadrado MJ. Cerebral manifestations in the antiphospholipid (Hughes) syndrome. Rheum Dis Clin N Am. 2006;32(3):465-90. [ Links ]
4. Fetoni V, Grisoli M, Salmaggi A, Carriero R, Girotti F. Clinical and neuroradiological aspects of Sneddon's syndrome and primary antiphospholipid antibody syndrome. A follow-up study. Neurol Sci. 2000;21(3):157-64. [ Links ]
5. Caldas CA, de Carvalho JF. Primary antiphospholipid syndrome with and without Sneddon's syndrome. Rheumatol Int. 2011;31(2):197-200. [ Links ]
6. Kalashnikova LA, Korczyn AD, Shavit S, Rebrova O, Reshetnyak T, Chapman J. Antibodies to prothrombin in patients with Sneddon's syndrome. Neurology. 1999;53(1):223-5. [ Links ]
7. Francès C, Piette JC. The mystery of Sneddon Syndrome: relationship with antiphospholipid syndrome and systemic lupus erythematosus. J Autoimmun. 2000;15(2):139-43. [ Links ]
8. Kalashnikova LA, Aleksandrova EN, Novikov AA, Dobrynina LA, Nasonov EL, Sergeeva EV, et al. [Anti-phosphatidylethanolamine antibodies in patients with Sneddon's syndrome]. Klin Med (Mosk). 2005;83(5):46-9. Russian. [ Links ]
9. Francès C, Papo T, Wechsler B, Laporte JL, Biousse V, Piette JC. Sneddon syndrome with or without antiphospholipid antibodies. A comparative study in 46 patients. Medicine (Baltimore). 1999;78(4):209-19. [ Links ]
Orlando Graziani Povoas Barsottini
Avenida Brigadeiro Luiz Antonio, 4.454 Jardim Paulista
Zip code: 01402-002 São Paulo (SP), Brazil
Phone: (5511) 3887-0066
Received on: Sep 12, 2012
Accepted on: Mar 7, 2012